News Delayed TNBC readout for Datroway delivers survival benefit AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.
News Enhertu scores again in early breast cancer AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.
News Lilly brings second oral SERD to market for breast cancer Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.
News Roche's oral SERD comes good in 2nd-line breast cancer trial Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.
News Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.
News AI picks up interval breast cancers missed by scans An AI could help to detect aggressive interval breast cancers that are diagnosed in between routine screening appointments, say US researchers.
Digital FH25: Jessica DaMassa on hosting, hype, and health innovatio... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with WTF Health founder and event emcee, Jessica DaMassa
Digital Sponsored Tracking studies get smarter: AI meets human intelligence Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market